Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB092 in Primary Tauopathy Syndromes
NCT03658135Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Corticobasal Syndrome (CBS), primary progressive aphasia, nonfluent variant (nfvPPA), Fronto-temporal lobar degeneration (FTLD) and 1 more comparing BIIB092 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 20 weeks. Started Sep 2018; status: terminated.
02
Drugs
gosuranemab
03
Conditions
Corticobasal Syndrome (CBS)primary progressive aphasia, nonfluent variant (nfvPPA)Fronto-temporal lobar degeneration (FTLD)traumatic encephalopathy syndrome (TES)
Beyond the preview
Go deeper on NCT03658135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658135.